On February 12, 2026, Quince Therapeutics reported having $5.8 million in cash and $11.9 million in short-term investments, while they owe $16.4 million on a loan. They are exploring strategic alternatives, including a possible reverse merger, due to unsuccessful clinical trials of their lead drug candidate.